|
|
|
 |
|
|
| News & Views |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Top Stories |
|
|
|
|
|
|
|
|
|
|
| Finance Tools |
|
|
|
|
|
|
|
|
|
|
| Search |
|
|
|
|
|
|
About Us
|
|
|
|
|
|
|
|
|
| Other Digital Look Sites |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Day Low/High | 3,263.00p/3,285.50p |
|
|
|
| 52 wk Low/High | 2,690.50p/3,348.00p |
|
|
|
| All prices are delayed by 15 mins |
|
| Price Data |
|
Market Data |
| Change Over |
|
Chg |
%Chg |
| 1 week | | 60.50p | +1.88 |
| 1 month | | -5.00p | -0.15 |
| 1 year | | 447.50p | +15.82 |
|
|
|
|
|
|
|
|
|
|
| Company News | Related Market News |
|
-
Thu 02 Sep 2010
AstraZeneca has received approval from the European Commission (EC) for its schizophrenia and bipolar drug Seroquel XR as an add-on treatment for major depressive episodes where antidepressants haven’t worked.
-
Tue 31 Aug 2010
AstraZeneca is mulling its options over fledgling respiratory treatment motavizumab after US regulators asked for more data on its efficacy.
-
Fri 13 Aug 2010
Panmure Gordon draws attention to press reports in the US which claim that drugs giant AstraZeneca has received enquiries from the US Department of Justice (DoJ) in relation to a wider corruption probe, and suggests any market over-reaction could present a buying opportunity.
-
Mon 09 Aug 2010
Drug giant AstraZeneca said it had agreed to pay a total of $198m (£124m) in compensation to about 17,500 claimants in the US in relation to its bipolar disorder treatment Seroquel.
-
Thu 29 Jul 2010
A bunch of forecast beating corporate results are giving Europe’s leading exchanges a lift in midday dealings.
-
Thu 29 Jul 2010
Europe’s main markets are cautiously higher in early dealings on Thursday as investors consider a bunch of corporate figures.
-
Thu 29 Jul 2010
AstraZeneca’s potential blockbuster heart drug Brilinta has received the backing of a US advisory panel just as the drug giant increased 2010 earnings targets for a second time this year following a strong performance from emerging markets and key drugs in the second quarter.
-
Wed 28 Jul 2010
Anglo-Dutch titan Royal Dutch Shell is the last of the major integrated oil companies to report in the current results season. Until the recent Gulf of Mexico oil spill debacle it had been languishing somewhat in the shadow of long time rival BP but the travails of its beleaguered rival has taken some of the heat off it.
-
Wed 30 Jun 2010
Panmure Gordon has doffed its hat to AstraZeneca’s legal eagles after the drugs giant’s favourable verdict in a Delaware court on its CRESTOR patent.
-
Wed 30 Jun 2010
Shares in AstraZeneca jumped nearly 10% after the Anglo-Swedish drugs giant received a favourable US ruling in its battle to keep control of the patents to its best-selling cholesterol-lowering drug Crestor.
|
| |
|
|
|
|
Snapshot 